All In Biotech

NDA 050802 · Bausch

Ziana

Clindamycin Phosphate, Tretinoin · Topical · Retinoid

Last checked: Nov 19, 2026Latest source record: Mar 25, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Nov 7, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

154

59 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 15, 2026.

ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. ZIANA ® Gel is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older. ( 1 )

Mechanism: Clindamycin [See Microbiology (12.4) .] Tretinoin Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZIANA · CLINDAMYCIN PHOSPHATE 1.2%; TRETINOIN 0.025% · GEL, TOPICAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective17
  • acne11
  • headache8
  • nausea8
  • pain7
  • diarrhoea6
  • dizziness6
  • dry skin6
  • erythema6
  • application site erythema5
  • application site pain5
  • flushing5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20082
20093
20103
20113
20127
20137
201423
201520
201640
20176
20189
20197
20205
20215
20226
20233
20241
20251
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ziana (Clindamycin/Tretinoin)

2024 spending

$8K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$11.54 per unit

View as table
YearSpending
2020$9,393
2021$5,200
2022$7,997
2023$9,807
2024$8,305

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.